Serum XXXX in malignant lymphoproliferative disorders.

@entity1 @entity2214 @entity981 @entity66 @entity706 @entity5 @entity2262 @entity1072 @entity381 @entity382 @entity1893 @entity236 @entity978
Serum @entity2262 (S-beta 2M) was measured at diagnosis in 44 @entity1 with @entity2214 and 47 with @entity706 . Among @entity1 with @entity1072 ( @entity1072 ) S-beta 2M was raised (greater than 3 mg/l) in 74% and in 23.5% of those with @entity981 ( @entity981 ). The frequencies for @entity1893 ( @entity1893 ) and @entity978 ( @entity978 ) were 59.2% and 40%, respectively. In @entity1072 patients high serum values correlated with large @entity5 mass, as estimated by Rai's clinical criteria (P less than 0.001), by total peripheral lymphocytes (r = 0.41, P less than 0.05) and by the percentage of bone marrow infiltration of the lymphocytes (P less than 0.01). A significant relation was also found in @entity1072 @entity1 between S-beta 2M level and survival (P less than 0.05). In @entity981 no association was found between S-beta 2M level with peripheral lymphoblast concentration, French-American-British (FAB) subclassification, @entity381 , and survival. In @entity1893 @entity1 a significant association was found between S-beta 2M levels and stage of disease (P less than 0.01) and an obscure relation (P less than 0.1) with the presence of lymph nodes greater than 3 cm in diameter, @entity381 , and @entity382 . No significant association was found between S-beta 2M level and histologic subtypes, presence of B symptoms, bone @entity236 , and survival. In @entity978 @entity1 a significant association was found between the level of S-beta 2M and stage of disease (P less than 0.05) and presence of @entity381 (P less than 0.05). No association was found between S-beta 2M level and histologic subtypes, lymph nodes greater than 3 cm in diameter, bone @entity236 , and B symptoms. A significant relation was found between S-beta 2M level and survival in @entity978 @entity1 with @entity66 (P less than .025).
